Astigmatism Research Today is a free monthly online journal that collates and summarizes the latest research about Astigmatism, including details on cornea, retina, treatment, types, signs, tests. | ||||||||
|
Efficacy of neural vision therapy to enhance contrast sensitivity function and visual acuity in low myopia.Tan DT, Fong A Department of Ophthalmology, Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore. snecdt@pacific.net.sg PURPOSE: To evaluate the efficacy and safety of neural vision enhancement technology (NVC, NeuroVision, Inc.) to improve visual acuity and contrast sensitivity function in eyes with low myopia. SETTING: Singapore Eye Research Institute, Singapore, Singapore. METHODS: This noncomparative interventional case series comprised 20 Asian adults between 19 and 53 years of age with low myopia (cycloplegic spherical equivalence [SE] from -0.5 diopter [D] to -1.5 D in the worst eye; astigmatism not exceeding 0.5 D in either eye; uncorrected visual acuity [UCVA] < or =0.7 logMAR) who had NVC treatment. The main outcome measures were distance UCVA, uncorrected contrast sensitivity, refraction, accommodative amplitude, and safety. RESULTS: All eyes had improvement in UCVA and contrast sensitivity. After treatment, the mean distance UCVA improved by a mean of 2.1 lines on the Early Treatment Diabetic Retinopathy Study logMAR chart. The mean contrast sensitivity improved over a range of spatial frequencies on sine-wave contrast sensitivity chart testing (1.5 to 18 cycles per degree). Follow-up data up to 12 months posttreatment showed that the gains were retained. Treatment did not alter refraction (mean spherical equivalent) or accommodative amplitudes. No adverse effects were reported. CONCLUSION: Preliminary evidence suggests NVC treatment is safe and improves UCVA and uncorrected contrast sensitivity in adult patients with low myopia. Published 25 March 2008 in J Cataract Refract Surg, 34(4): 570-7.
© 2005-2008 Astigmatism Research Today. All Rights Reserved. |
| ||||||
